Article

Validity of Expanded Program on Immunization Contact Method health behavior estimates in Mali.

Preventive Medicine Residency Program, Scientific Education and Professional Development Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
The Journal of Infectious Diseases (Impact Factor: 5.85). 03/2012; 205 Suppl 1:S112-9. DOI: 10.1093/infdis/jir797
Source: PubMed

ABSTRACT In the developing world, household surveys provide high-quality health behavior data integral to public health program management. The Expanded Program on Immunization Contact Method (EPI-CM) is a proposed, less resource-intensive method in which health center staff incorporate health behavior questions into routine vaccination activities. No systematic evaluation of EPI-CM validity has yet been conducted.
We used concurrent household survey and EPI-CM to collect data on 4 infant health behaviors in Mali at 2 time points (8 total comparisons). Studied health behaviors were bednet use, obtaining care for fever, obtaining care for a respiratory complaint, and using oral rehydration solution for diarrhea. Household survey and EPI-CM estimates were considered equivalent if a 95% confidence interval about the difference in estimated proportions fell within the interval (-.10, .10).
EPI-CM estimates were higher than household survey estimates for 7 of 8 unadjusted paired estimates; estimates of bednet use in 2009 met a priori equivalence criteria in a setting of high bednet use (90.5%). When we restricted household survey data to infants up-to-date on vaccinations, estimates for behaviors other than bednet use remained substantially different.
We were unable to demonstrate that EPI-CM, as implemented, consistently produces data comparable with household survey data.

0 Bookmarks
 · 
70 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Active control equivalence studies, with the goal of demonstrating therapeutic equivalence between a new and an active control treatment, are becoming more widespread due to current therapies that reflect previous successes in the development of new treatments. Because ethical requirements preclude the use of a placebo or no-treatment control for internal study validation, certain methodologic issues arise in active control equivalence trials that require special attention. We emphasize a special feature of this alternative study design, namely, its reliance on an implicit "historical control assumption". To conclude that a new drug is efficacious on the basis of an active control equivalence study (ACES) requires a fundamental assumption that the active control drug would have performed better than a placebo, had a placebo been used in the trial. In designing an ACES, one needs some assurance that historical estimates of the active control drug's efficacy relative to placebo are applicable to the new experimental setting. Steps that can be taken to compile such evidence and to justify the use of an active control equivalence design are described. These issues are illustrated in the context of a planned study to evaluate the efficacy of a new drug for the prevention of stroke, using aspirin as an active control.
    Journal of Clinical Epidemiology 02/1989; 42(6):503-11. · 5.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We introduce an innovative method that uses personal digital assistants (PDAs) equipped with global positioning system (GPS) units in household surveys to select a probability-based sample and perform PDA-based interviews. Our approach uses PDAs with GPS to rapidly map all households in selected areas, choose a random sample, and navigate back to the sampled households to conduct an interview. We present recent field experience in two large-scale nationally representative household surveys to assess insecticide-treated bed net coverage as part of malaria control efforts in Africa. The successful application of this method resulted in statistically valid samples; quality-controlled data entry; and rapid aggregation, analyses, and availability of preliminary results within days of completing the field work. We propose this method as an alternative to the Expanded Program on Immunization cluster sample method when a fast, statistically valid survey is required in an environment with little census information at the enumeration area level.
    The American journal of tropical medicine and hygiene 09/2007; 77(2):393-9. · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assist the Central African Republic (CAR) develop national guidelines for treating children with pneumonia, a survey was conducted to determine antimicrobial resistance rates of nasopharyngeal isolates of Streptococcus pneumoniae (SP) and Haemophilus influenzae (HI). Secondary purposes of the survey were to identify risk factors associated with carriage of a resistant isolate and to compare the survey methods of including only children with pneumonia vs. including all ill children. A cross-sectional survey of 371 ill children was conducted at 2 outpatient clinics in Bangui, CAR. In all 272 SP isolates and 73 HI isolates were cultured. SP resistance rates to penicillin, trimethoprim-sulfamethoxazole (TMP-SMX), tetracycline and chloramphenicol were 8.8, 6.3, 42.3 and 9.2%, respectively. All penicillin-resistant SP isolates were intermediately resistant. HI resistance rates to ampicillin, TMP-SMX and chloramphenicol were 1.4, 12.3 and 0%, respectively. The most common SP serotypes/groups were 19, 14, 6 and 1; 49% of HI isolates were type b. History of antimicrobial use in the previous 7 days was the only factor associated with carriage of a resistant isolate. Resistance rates were similar among ill children regardless of whether they had pneumonia. Resistance rates were low for antimicrobials recommended by the World Health Organization for children with pneumonia. We recommended TMP-SMX as the first line treatment for pneumonia in CAR because of its low cost, ease of dosing and activity against malaria.
    The Pediatric Infectious Disease Journal 06/2000; 19(5):438-44. · 3.14 Impact Factor